NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free TRDA Stock Alerts $15.37 -0.22 (-1.41%) (As of 09:38 AM ET) Add Compare Share Share Today's Range$15.37▼$15.3750-Day Range$11.85▼$16.3852-Week Range$10.75▼$18.44Volume888 shsAverage Volume75,237 shsMarket Capitalization$518.89 millionP/E Ratio24.40Dividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Entrada Therapeutics alerts: Email Address Entrada Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside34.7% Upside$21.00 Price TargetShort InterestBearish9.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$188,963 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.14) to ($3.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 starsMedical Sector510th out of 904 stocksPharmaceutical Preparations Industry240th out of 427 stocks 3.5 Analyst's Opinion Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.08% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 21.4, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 3.49%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRDA. Previous Next 2.3 News and Social Media Coverage News SentimentEntrada Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Entrada Therapeutics this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold 24.95% more of their company's stock than they have bought. Specifically, they have bought $151,227.00 in company stock and sold $188,963.00 in company stock.Percentage Held by InsidersOnly 7.58% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from ($0.14) to ($3.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is 24.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is 24.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 111.49.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBill Clinton Backing Biden Replacement???According to Louis, it’s a near-certainty that just enough Republicans will abandon Trump to ensure his defeat. But Biden supporters shouldn’t break out the champagne, either… according to Louis’s shock finding, Biden is toast, too.This shocking video reveals exactly how. About Entrada Therapeutics Stock (NASDAQ:TRDA)Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More TRDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRDA Stock News HeadlinesMay 21, 2024 | insidertrades.comNatarajan Sethuraman Sells 1,000 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockMay 11, 2024 | insidertrades.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Acquires $31,955.04 in StockJune 6, 2024 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Shares Gap Down to $15.70June 3, 2024 | globenewswire.comEntrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceMay 17, 2024 | finance.yahoo.comDirector Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)May 16, 2024 | globenewswire.comEntrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 8, 2024 | markets.businessinsider.comEntrada Therapeutics is about to announce earnings — here's what Wall Street expectsMay 8, 2024 | finance.yahoo.comEntrada Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 7, 2024 | investorplace.comTRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comEntrada Therapeutics Reports First Quarter 2024 Financial ResultsApril 14, 2024 | nasdaq.comFriday 4/12 Insider Buying Report: ATOS, TRDAApril 12, 2024 | insidermonkey.comInsiders are Piling into These 5 Healthcare Stocks in 2024April 11, 2024 | msn.comInsiders Buying America's Car-Mart And 2 Other StocksMarch 27, 2024 | finance.yahoo.comDirector Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)March 19, 2024 | finance.yahoo.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's EstimatesMarch 18, 2024 | markets.businessinsider.comEntrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical PipelineMarch 13, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)March 13, 2024 | finanznachrichten.deEntrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comRecap: Entrada Therapeutics Q4 EarningsMarch 13, 2024 | globenewswire.comEntrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 23, 2024 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Insider TradesJanuary 29, 2024 | finance.yahoo.com‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 StocksJanuary 8, 2024 | finance.yahoo.comAmicus (FOLD) Issues Preliminary Revenue Results for FY23January 6, 2024 | msn.comOppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform RecommendationJanuary 3, 2024 | finance.yahoo.comBEAM Stock Rallies More Than 25% in 3 Months: What Next?See More Headlines Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/11/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRDA CUSIPN/A CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$22.00 Low Stock Price Target$20.00 Potential Upside/Downside+34.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.63 Trailing P/E Ratio24.75 Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,680,000.00 Net Margins14.42% Pretax Margin24.87% Return on Equity9.73% Return on Assets4.80% Debt Debt-to-Equity RatioN/A Current Ratio2.38 Quick Ratio2.38 Sales & Book Value Annual Sales$129.01 million Price / Sales4.08 Cash FlowN/A Price / Cash FlowN/A Book Value$7.26 per share Price / Book2.15Miscellaneous Outstanding Shares33,760,000Free Float31,200,000Market Cap$526.32 million OptionableOptionable Beta-0.23 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Dipal Doshi (Age 48)CEO & Director Comp: $968.21kMr. Nathan J. Dowden (Age 53)President & COO Comp: $694.3kDr. Natarajan Sethuraman Ph.D. (Age 62)Chief Scientific Officer Comp: $694.3kMr. Kory James Wentworth CPA (Age 45)CFO & Treasurer Dr. Jared Cohen J.D.Ph.D., General CounselMs. Kerry Robert M.S.Senior Vice President of PeopleMs. Karla MacDonaldChief Corporate Affairs OfficerMr. Kevin Healy Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsAmphastar PharmaceuticalsNASDAQ:AMPHAmneal PharmaceuticalsNASDAQ:AMRXRocket PharmaceuticalsNASDAQ:RCKTArvinasNASDAQ:ARVNZai LabNASDAQ:ZLABView All CompetitorsInsiders & InstitutionsNatarajan SethuramanSold 9,675 sharesTotal: $146,963.25 ($15.19/share)Dipal DoshiSold 1,800 sharesTotal: $27,000.00 ($15.00/share)Natarajan SethuramanSold 1,000 sharesTotal: $15,000.00 ($15.00/share)California State Teachers Retirement SystemSold 1,579 shares on 5/16/2024Ownership: 0.037%Price T Rowe Associates Inc. MDSold 256,316 shares on 5/15/2024Ownership: 8.156%View All Insider TransactionsView All Institutional Transactions TRDA Stock Analysis - Frequently Asked Questions Should I buy or sell Entrada Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRDA shares. View TRDA analyst ratings or view top-rated stocks. What is Entrada Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 1-year price objectives for Entrada Therapeutics' shares. Their TRDA share price targets range from $20.00 to $22.00. On average, they predict the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 34.7% from the stock's current price. View analysts price targets for TRDA or view top-rated stocks among Wall Street analysts. How have TRDA shares performed in 2024? Entrada Therapeutics' stock was trading at $15.09 at the beginning of the year. Since then, TRDA stock has increased by 3.3% and is now trading at $15.59. View the best growth stocks for 2024 here. When is Entrada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our TRDA earnings forecast. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) released its quarterly earnings results on Tuesday, May, 7th. The company reported $0.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $1.06. The company earned $59.12 million during the quarter, compared to analyst estimates of $25 million. Entrada Therapeutics had a net margin of 14.42% and a trailing twelve-month return on equity of 9.73%. What ETF holds Entrada Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 1,304 shares of TRDA stock, representing 0.56% of its portfolio. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Entrada Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (8.16%), Vanguard Group Inc. (3.20%), Allspring Global Investments Holdings LLC (0.04%), Allspring Global Investments Holdings LLC (0.04%), California State Teachers Retirement System (0.04%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, John F Crowley, Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher and Peter S Kim. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRDA) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBill Clinton Backing Biden Replacement???According to Louis, it’s a near-certainty that just enough Republicans will abandon Trump to ensure his defeat...The Freeport Society | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.